Pharmacy Tech Scholar
SEPTEMBER 9, 2020
New York Pharmacy Technician Requirements *Completing the PharmacyTechScholar.com Online Course and Passing the PTCE meets the proposed 2021 credentialing/training requirements in New York New York… The post New York Pharmacy Technician Requirements appeared first on PharmacyTechScholar.com.
pharmaphorum
SEPTEMBER 10, 2020
Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that they say could serve as a first line of defense against coronavirus infections. The nasal spray could provide protection from infection within a few days of administration, and would be easy to make in bulk at a low cost, say the partners. The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the viru
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
SEPTEMBER 8, 2020
The company has submitted an investigational new drug application for FSD201, a possible therapy for patients with severe cases of the virus.
Druggist
SEPTEMBER 7, 2020
Insomnia is a common sleep disorder, which is characterised by a difficulty in getting to sleep or maintaining the sleep (waking up at night or early in the morning). Sedative antihistamines can be used as a temporary aid to help with sleeping problems. In this post, I will review all over the counter sleeping pills (OTC) available in the UK. All of the non-prescription sleeping pills available in the UK contain sedative antihistamines.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
SEPTEMBER 9, 2020
The drug's cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
pharmaphorum
SEPTEMBER 7, 2020
Laura Morrill from ECI Partners looks at why data and technology are the keys to success in pharma services post-COVID. The pharmaceuticals industry has, for some time, been behind the curve when it comes to the adoption of technology. High barriers to entering the sector and high levels of regulation are just two factors that have meant that there has often been an “innovation lag” when it comes to implementing new technologies and embracing technological and digital change in the pharma indust
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Mirror
SEPTEMBER 10, 2020
There is an ongoing pandemic that has been proven to harm and even kill many people. Researchers have found that the elderly are particularly susceptible to the COVID-19 virus that caused the epidemic. This is because they often have weaker immune systems, so they can’t fight off a viral infection easily. This new situation puts. The post How Can Nursing Homes Protect Themselves from COVID-19?
indispensable health
SEPTEMBER 8, 2020
Pre-Interview Tips for Pharmacy Professionals | Tip #2 with Tom Alig | Vice President of Staffing at Indispensable Health I am Tom Alig, VP of Staffing with Indispensable Health. I’ve been recruiting pharmacists and pharmacy technicians since 2004, and I’ve seen the things good candidates do to separate themselves, and I’ve seen the mistakes that some candidates make.
pharmaphorum
SEPTEMBER 11, 2020
Brent Saunders has been out of the limelight for a few months since departing Allergan after its takeover by AbbVie, but now he is back in a leading role at Vesper Healthcare Acquisition, set up to acquire assets in the healthcare sector. Delaware-incorporated Vesper has filed a with a $400 million initial public offering (IPO) and plans to list on the Nasdaq under the symbol VSRU, with Goldman Sachs and JP Morgan acting as bookrunners.
Outsourcing Pharma
SEPTEMBER 10, 2020
The company is delving into clinical research partnerships geared toward saving the lives of soldiers, eventually translating findings to civilian care.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
SEPTEMBER 10, 2020
The proposed deal covers the initial supply of 200 million doses and an option to purchase an additional 100 million, with deliveries starting by the end of 2020, if the vaccine is approved
Med Ed 101
SEPTEMBER 9, 2020
When most healthcare professionals think about drug interactions, we tend to think about an issue arising when a medication is added to the regimen. A perfect example is the warfarin Bactrim interaction. Here’s a case scenario involving cholestyramine and warfarin that you might not necessarily think about. A 77-year-old female has a history of chronic […].
pharmaphorum
SEPTEMBER 8, 2020
An EU consumer body has urged the European Commission to keep compensation measures in place for people who might be harmed in COVID-19 vaccine trials, responding to reports that the drug industry is lobbying to reduce liability. In a letter to the Commissioner for Health and Food Safety Stella Kyriakides, the BEUC says that even though the need for a coronavirus vaccine is urgent, access “must go hand in hand with adequate consumer compensation in case of harm.”.
Outsourcing Pharma
SEPTEMBER 9, 2020
The clinical-stage biotech firm is investigating early efficacy of its Cymerus mesenchymal stem cells for treatment of severe COVID-19 patients.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
SEPTEMBER 7, 2020
The personalised cancer treatment has received conditional approval in the US
Med Ed 101
SEPTEMBER 6, 2020
Parkinson’s disease can be very debilitating and not understanding how medications should be dosed can compound the problem. Let’s review the pharmacology briefly and why you need to be careful with Sinemet 10/100. In Parkinson’s, we have a dopamine shortage. Levodopa is converted to dopamine in the brain but before it can get to the […].
pharmaphorum
SEPTEMBER 10, 2020
September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it is critical to the future success of the life sciences sector. Taking diversity and inclusion seriously, supported by robust policies and accountability for implementation, creates success for everyone, fostering happy, healthy and invested employees, new ways of thinking and opportunities for growth, learning
Outsourcing Pharma
SEPTEMBER 9, 2020
The Inspire Research Accelerator is designed to let academic researchers anywhere in the world to collaborate with the company.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
SEPTEMBER 9, 2020
The funds will be used to improve single-cell RNA sequencing
pharmaphorum
SEPTEMBER 7, 2020
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preliminary results published in The Lancet are from a non-randomised phase 1/2 trial of 76 people aged 18-60, which found an antibody response within 21 days and no serious adverse events after 42 days.
pharmaphorum
SEPTEMBER 9, 2020
Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. For some people, a job is more than just a job.
pharmaphorum
SEPTEMBER 8, 2020
Sandoz’s Pierre Bourdage looks at the unexpected secondary impacts of COVID-19 on countries and healthcare systems, and asks how pharma can help improve sustainability to tackle them. It is undeniable that the COVID-19 pandemic has had a tremendous impact on all aspects of our lives, with ripple effects continuing to evolve. Faced with constant and overwhelming information about the pandemic, including rapidly changing policy responses, there is also an alarming acceleration of a healthcare sust
pharmaphorum
SEPTEMBER 11, 2020
It’s 2020 and the digital revolution is well on its way. Yet, for clinical trials worldwide, real-time access to data is not the norm – and that lack can create a cascading set of issues affecting every aspect of a study. Critical decisions are too often being made in a digital data vacuum. At best, processes are not as efficient as they could be; at worst, serious problems may go undetected for weeks or even months.
pharmaphorum
SEPTEMBER 11, 2020
Health systems in lower-income countries could overtake those in richer countries with AI-enabled technologies, according to a report from Novartis Foundation and Microsoft. Technologies such as mobile phone trading platforms, e-banking, e-commerce, and even blockchain applications have often been adopted more quickly and comprehensively in low- and middle-income countries than in high-income countries, the report found.
pharmaphorum
SEPTEMBER 11, 2020
Roche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Ocrevus. Ocrevus (ocrelizumab) was approved in 2017 for relapsing and primary progressive forms of MS and is seen as one of the most successful drug launches in pharma history, generating sales of $3.79 billion in 2019 with more growth predicted this year.
pharmaphorum
SEPTEMBER 10, 2020
September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it is critical to the future success of the life sciences sector. Taking diversity and inclusion seriously, supported by robust policies and accountability for implementation, creates success for everyone, fostering happy, healthy and invested employees, new ways of thinking and opportunities for growth, learning
pharmaphorum
SEPTEMBER 9, 2020
A company that has developed a digital treatment for pain and anxiety – Belgium-based Oncomfort – has raised €10 million in first-round financing that will be used to fund international growth. Oncomfort has created a platform called Sedakit that provides ‘digital sedation’ – clinical hypnotherapy sessions delivered via a virtual reality headset accompanied by scripts and immersive sounds designed to dissociate patients from their symptoms.
pharmaphorum
SEPTEMBER 8, 2020
The UK government is to invest £32 million ($41.5 million) in six health technology projects aiming to transform care for debilitating diseases such as cancer and osteoarthritis. Projects include a novel artificial intelligence (AI) X-ray scanner to diagnose cancer and osteoarthritis more effectively and robotic muscles to assist those who have suffered from a stroke.
pharmaphorum
SEPTEMBER 9, 2020
Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. For some people, a job is more than just a job.
pharmaphorum
SEPTEMBER 8, 2020
Verona Pharma is starting a pilot study of its inhaled respiratory diseases drug ensifentrine in patients hospitalised with COVID-19. The Anglo-American biotech is already developing ensifentrine in chronic obstructive pulmonary disease (COPD), but the company believes it could also help to relieve respiratory symptoms associated with viruses such as SARS-CoV-2.
pharmaphorum
SEPTEMBER 9, 2020
It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than six people to contain growing numbers of new cases and the lead vaccine trial from AstraZeneca was halted because of a safety concern. Shares in AstraZeneca slid following the news that the company had voluntarily paused a phase 3 trial in the US, which was first revealed by the trade website Stat.
pharmaphorum
SEPTEMBER 7, 2020
AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech. The US drugmaker is paying $200 million upfront for lemzoparlimab, which targets CD47 – an immune checkpoint on malignant cells that helps them evade being destroyed by immune cells such as macrophages. It has also pledged another $1.74 billion in payments due if the drug achieves development and sales objectives. $20 million of the upfront fee is tied
pharmaphorum
SEPTEMBER 10, 2020
Health systems in lower-income countries could overtake those in richer countries with artificial intelligence (AI)-enabled technologies, according to a report from Novartis Foundation and Microsoft. According to the report “Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity” , technologies such as mobile phone trading platforms, e-banking, e-commerce and blockchain applications have been adopted faster and more comprehensively in low- and middle-income countri
Expert insights. Personalized for you.
221 
Let's personalize your content